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Abstract
Background: Pertussis (whooping cough) is well known to be underreported, particularly among adults, who can
act as an infectious reservoir, potentially putting susceptible newborns at risk of serious illness. The purpose of this
study was to estimate the seroprevalence of pertussis in adults in Hungary.
Methods: This epidemiological, cross-sectional study was conducted in adults in five general practitioners’ practices in
Hungary. Serum anti-pertussis toxin immunoglobulin G (anti-PT IgG) antibody levels were analyzed using enzyme-linked
immunosorbent assay. Sera were classified following manufacturer’s instructions as: strongly indicative of current/recent
infection (≥1.5 optical density [OD] units); indicative of current/recent infection (≥1.0 OD units); seropositive (>0.3 OD
units); or seronegative (≤0.3 OD units). Logistic regression was performed to describe the associations between
seroprevalence and various characteristics.
Results: Between 24th April 2014 and 24th April 2015, 1999 adults (60.6% female; mean age 47.4 ± 17.7 years) were
included in the analysis. A total of 14.8% were seropositive for anti-PT IgG, 1.1% had a level indicative of current/recent
infection, and 0.1% had a level strongly indicative of current/recent infection. Logistic regression showed significant
relationships between increased rates of seropositivity and: age ≥60 years (odds ratio [OR], 1.97; 95% confidence interval
[CI], 1.39–2.80; p = .0002) or 18–29 years (OR, 1.67; 95% CI, 1.13–2.46; p = .0094) vs. 45–59 years; former smoker (OR, 1.46;
95% CI, 1.08–1.97; p = .014) or current smoker (OR, 1.38; 95% CI, 1.01–1.89; p = .045) vs. never smoker; and male (OR, 1.30;
95% CI, 1.01–1.68; p = .041) vs. female. Also, between increased rates of probable current/recent infection and current
smoker (OR, 7.50; 95% CI, 2.32–24.31; p = .0008) or former smoker (OR, 4.07; 95% CI, 1.21–13.64; p = .023) vs. never smoker.
Conclusions: Approximately 85% of the adults studied were seronegative and therefore susceptible to pertussis infection.
Approximately 1% had anti-PT IgG levels indicative of current/recent pertussis infection, which could potentially be
transmitted to susceptible young infants. Vaccination of adults is a key way to indirectly protect infants.
Trial registration: Clinical Trials.gov NCT02014519. Prospectively registered 12 December 2013.
Keywords: Seroprevalence, Bordetella pertussis, Epidemiology, Hungary
Background
Pertussis (whooping cough) is an acute respiratory tract
infection caused by Bordetella pertussis that is character-
ized by a chronic, severe cough [1]. As pertussis is a
potentially life-threatening infection for newborns and
unvaccinated infants [2], vaccination during infancy is
recommended. In Hungary, pertussis immunization –
using a combined diphtheria-tetanus-whole cell pertussis
vaccine – was introduced in 1953 [3]. This had a huge
beneficial impact on pertussis incidence [3]. In 2006, this
was switched to a combined diphtheria-tetanus-acellular
pertussis vaccine [4]. The optimum immunization sched-
ule for pertussis is unclear, so these vary by country; in
Hungary, the current recommended immunization sched-
ule includes acellular pertussis at ages 2, 3, and 4 months,
with boosters at ages 1.5, 6, and 11 years [5]. Coverage of
all doses in Hungary is very high (>99%) [6].
However, adults are at risk of pertussis infection due to
waning immunity following immunization or natural
* Correspondence: monica.x.tafalla@gsk.com
3GSK, Avenue Fleming 20, Wavre 1300, Belgium
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Torzsa et al. BMC Infectious Diseases  (2017) 17:242 
DOI 10.1186/s12879-017-2356-2
infection [7–10]. Although pertussis during adulthood is
generally not serious, it can result in morbidity and –
more importantly – infected adults can pass on the infec-
tion to infants who have not been (fully) vaccinated [9].
Some European countries have therefore introduced vari-
ous combinations of: adolescent, adult, or elderly boosters;
a “cocooning strategy” (vaccination of household members
in contact with a newborn); or vaccination of pregnant
women (to provide the infant with placentally transmitted
antibodies) [11, 12]. Apart from the introduction of adoles-
cent boosters, these strategies have not yet been recom-
mended in Hungary [11]. Given that the notification rate in
infants (age <1 year) in Hungary was 2.24/100,000 in 2014,
roughly 12-fold higher than in those aged ≥1 year (approxi-
mately 0.18/100,000) [13], young infants are clearly still at
risk of pertussis despite high pediatric population vaccin-
ation coverage.
Although overall pertussis notification rates in
Hungary are among the lowest in Europe [13], at 0.17/
100,000 in 2015 [14, 15], it is well known that pertussis
is underreported, particularly among adults, who gener-
ally have much milder symptoms than infants, making it
difficult to distinguish from a common cold [16]. The
low notification rate of pertussis coupled with the high
immunization coverage may result in general practi-
tioners (GPs) in Hungary not testing adults with chronic
cough for pertussis. The true incidence of pertussis may
therefore be considerably higher than the notified cases,
particularly among adults.
A more realistic estimate of pertussis incidence can be
obtained from seroepidemiological studies; which can
also help in the determination of immunity duration, the
need for booster doses, and to investigate disease resur-
gence and its causes [17]. However, although high anti-
body titers are indicative of recent infection, lower levels
can be due to more distant infection or vaccination.
Although higher anti-pertussis toxin immunoglobulin G
(anti-PT IgG) levels have been correlated with protec-
tion against pertussis [18], there is no agreement on the
level of pertussis antibodies that confers protection
against pertussis. This makes the interpretation of anti-
body prevalence data challenging. A number of studies
have examined the seroprevalence of pertussis antigens
in various countries, but as no such studies have yet
been undertaken in Hungary, the purpose of this
seroepidemiological study was to estimate the seropreva-
lence of pertussis in adults in Hungary.
Methods
This epidemiological, cross-sectional study (NCT02014519)
was conducted in adults in five centers in Hungary.
Subjects were recruited from GP clinics between 24th April
2014 and 24th April 2015, mostly during a clinic visit for
another purpose, but some by telephone or email contact
(particularly in the youngest age group, due to difficulties in
recruitment). Subjects had to be aged ≥18 years and pro-
vide written informed consent; and not have been vacci-
nated against pertussis within the previous 12 months or
have a confirmed or suspected immunological disorder.
Serum anti-PT IgG levels were determined using a
commercial enzyme-linked immunosorbent assay
(ELISA) (PERTUSSCAN PT IgG, Euro Diagnostica AB,
Sweden) at the Laboratory of the National Epidemiology
Centre using standardized and validated procedures in
accordance with the manufacturer’s instructions [19].
Test results were used to classify sera according to
manufacturer pre-defined cut-off values as: strongly in-
dicative of current/recent infection (≥1.5 optical density
[OD] units; corresponds to 110 ELISA units [EU]/mL
against the United States (US) Food and Drug Adminis-
tration standard Lot 3 [19]); indicative of current/recent
infection (≥1.0 OD units [70 EU/mL]); seropositive (>0.3
OD units [18 EU/mL]; the sensitivity limit of the assay);
or seronegative (≤0.3 OD units).
The main aim of the study was to assess the seropreva-
lence of anti-PT IgG in adults in Hungary, according to
the cut-off levels defined above; this was also assessed ac-
cording to age category (18–29, 30–44, 45–59, and
≥60 years). Comparisons of seropositivity and anti-PT IgG
levels indicative of current/recent infection by age cat-
egory were tested using the Chi-square test. Relationships
between seropositivity and age category, gender, history of
vaccination against pertussis, history of pertussis infection,
medication (antibiotics related to respiratory infections,
prescribed and over-the-counter cough medicines) in the
previous 12 months, hospitalization due to respiratory in-
fections in the previous 12 months, and smoking status
were examined by a logistic regression analysis (using the
method of maximum likelihood to estimate the parame-
ters). The same was done for antibody levels indicative of
current/recent infection. In addition to the saturated
models (i.e., considering all of the potential factors), final
models using the backward elimination strategy (in which
a p-value of 0.20 is required to keep a potential factor in
the model) were also performed. Both models adjusted for
all other factors in the model, including confounders. A
p-value <.05 was taken to be statistically significant. All
statistical analyses were performed using SAS Version 9.2.
The target sample size was approximately 2000 sub-
jects (400 aged 18–29 years, 550 aged 30–44 years, 510
aged 45–59 years, 540 aged ≥60 years), based on a previ-
ous similar study in Israel [20].
Results
A total of 1999 subjects valid for analysis were enrolled
(one subject was excluded for violation of inclusion and
exclusion criteria). Demographics are shown in Table 1.
It should be noted that 836 subjects did not know their
Torzsa et al. BMC Infectious Diseases  (2017) 17:242 Page 2 of 8
vaccination status. Of those who knew whether they had
received a pertussis vaccination, 75.8% had been vacci-
nated. Only 5.6% of subjects who knew their pertussis
history reported having been previously diagnosed with
pertussis, most often as a child (86.2%). Among those
who were seropositive, none reported having been previ-
ously diagnosed with pertussis as an adult. Among those
who reported a long-lasting cough in the last 12 months
(8.3%), most (86.4%) reported that their cough had lasted
for ≥30 days and were dry (54.3%). Contact with a
person with a long-lasting cough in the previous
12 months was reported by 12.6% of subjects, mainly
with a family member (61.7%) and daily contact (67.8%).
Only 0.5% of the subjects had been hospitalized due to
respiratory infections in the previous 12 months, a
median (range) of 1 (1–5) times, for a median (range) of
9 (3–35) days.
A total of 295 subjects (14.8%) were seropositive for
anti-PT IgG (>0.3 OD units), 22 (1.1%) had a level
indicative of current/recent infection (≥1.0 OD units),
and 2 (0.1%) had a level strongly indicative of
current/recent infection (≥1.5 OD units) (Table 2).
Seropositivity (>0.3 OD units) varied significantly
across age groups (p = .0004), and was the highest
among those aged ≥60 years and 18–29 years; but
current/recent pertussis infection status (≥1.0 OD)
did not vary significantly by age (p = .096).
Various characteristics were significantly associated
with seropositivity (>0.3 vs. ≤0.3 OD units), namely age
(age 18–29 and ≥60 vs. 45–59 years), gender, and
smoking status (Table 3). For increased likelihood of
current/recent infection (≥1.0 vs. <1.0 OD units), only
smoking status remained significant after backward
elimination; although there was a trend towards increased
likelihood of current/recent infection among those aged
≥60 years (Table 4).
Discussion
In this Hungarian study, 14.8% of the healthy adults tested
(during 2014–2015) were seropositive (>0.3 OD units) for
anti-PT IgG. This is lower than has been reported in
seroprevalence studies in adults in other countries
(approximately 20–80% [20–27]). However, it should be
noted that these studies used a variety of different assays;
and the units and cut-offs used to define seropositivity
varied widely, which limits their comparability [16]. Fur-
ther, seropositivity for anti-PT IgG can be due to prior
pertussis infection or vaccination [28]. Although none of
the subjects in the current study had been vaccinated
against pertussis within the last year, this was not neces-
sarily the case for the other seroepidemiological studies.
Regardless of these issues, in the current study, 85.2% of
the adults tested were seronegative and therefore at risk of
Table 1 Characteristics of the study population, overall and by seropositivity for anti-PT IgG
Total (n = 1999) Seropositivea (n = 295) Seronegativeb (n = 1704)
Demographics
Age (years) 47.4 ± 17.7 48.8 ± 19.4 47.1 ± 17.4
Female 1212/1999 (60.6) 160/295 (54.2) 1052/1704 (61.7)
Pertussis-related history
Pertussis vaccination 882/1163 (75.8) 127/165 (77.0) 755/998 (75.7)
Prior pertussis 88/1566 (5.6) 15/227 (6.6) 73/1339 (5.5)
Infant 3/87 (3.4) 0 3/73 (4.1)
Child 75/87 (86.2) 13/14 (92.9) 62/73 (84.9)
Adolescent 3/87 (3.4) 1/14 (7.1) 2/73 (2.7)
Adult 6/87 (6.9) 0 6/73 (8.2)
Long-lasting coughc 164/1971 (8.3) 20/290 (6.9) 144/1681 (8.6)
Recent contact with a person with
pertussis/long-lasting coughc
227/1795 (12.6) 30/270 (11.1) 197/1525 (12.9)
Regular contact with children 919/1999 (46.0) 122/295 (41.4) 797/1704 (46.8)
Relevant medicationsd 241/1962 (12.3) 39/287 (13.6) 202/1675 (12.1)
Relevant hospitalizationse 10/1994 (0.5) 4/294 (1.4) 6/1700 (0.4)
Data are mean ± SD or n/N (%), where N is the number of subjects with known data
Abbreviations: Anti-PT IgG anti-pertussis toxin immunoglobulin G, OD optical density, SD standard deviation
a>0.3 OD units
b≤0.3 OD units
cLasting ≥3 weeks in the previous 12 months
dAny antibiotics and/or other medication (i.e., any cough medicines) for lower respiratory tract infections or (suspected) pertussis infections in the previous 12 months
eHospitalized due to respiratory infections in the previous 12 months
Torzsa et al. BMC Infectious Diseases  (2017) 17:242 Page 3 of 8
Ta
b
le
2
Su
bj
ec
ts
w
ith
an
ti-
PT
Ig
G
le
ve
ls
ab
ov
e/
be
lo
w
th
e
va
rio
us
cu
t-
of
fs
A
nt
i-P
T
Ig
G
le
ve
l
To
ta
l(
n
=
19
99
)
A
ge
gr
ou
ps
18
–2
9
ye
ar
s
(n
=
40
8)
30
–4
4
ye
ar
s
(n
=
54
1)
45
–5
9
ye
ar
s
(n
=
50
9)
≥
60
ye
ar
s
(n
=
54
1)
St
ro
ng
ly
in
di
ca
tiv
e
of
cu
rr
en
t/
re
ce
nt
in
fe
ct
io
n
(≥
1.
5
O
D
un
its
)
2
(0
.1
0
[0
.0
1–
0.
36
])
0
(0
.0
0
[0
.0
0–
0.
90
])
1
(0
.1
8
[0
.0
0–
1.
03
])
1
(0
.2
0
[0
.0
0–
1.
09
])
0
(0
.0
0
[0
.0
0–
0.
68
])
In
di
ca
tiv
e
of
cu
rr
en
t/
re
ce
nt
in
fe
ct
io
n
(≥
1.
0
O
D
un
its
)
22
(1
.1
0
[0
.6
9–
1.
66
])
2
(0
.4
9
[0
.0
6–
1.
76
])
5
(0
.9
2
[0
.3
0–
2.
14
])
4
(0
.7
9
[0
.2
1–
2.
00
])
11
(2
.0
3
[1
.0
2–
3.
61
])
Se
ro
po
si
tiv
e
(>
0.
3
O
D
un
its
)
29
5
(1
4.
76
[1
3.
23
–1
6.
39
])
67
(1
6.
42
[1
2.
96
–2
0.
38
])
67
(1
2.
38
[9
.7
3–
15
.4
6]
)
56
(1
1.
00
[8
.4
2–
14
.0
5]
)
10
5
(1
9.
41
[1
6.
16
–2
3.
00
])
Se
ro
ne
ga
tiv
e
(≤
0.
3
O
D
un
its
)
17
04
(8
5.
24
[8
3.
61
–8
6.
77
])
34
1
(8
3.
58
[7
9.
62
–8
7.
04
])
47
4
(8
7.
62
[8
4.
54
–9
0.
27
])
45
3
(8
9.
00
[8
5.
95
–9
1.
58
])
43
6
(8
0.
59
[7
7.
00
–8
3.
84
])
D
at
a
ar
e
n
(%
[9
5%
C
I])
A
bb
re
vi
at
io
ns
:A
nt
i-P
T
Ig
G
an
ti-
pe
rt
us
si
s
to
xi
n
im
m
un
og
lo
bu
lin
G
,C
Ic
on
fid
en
ce
in
te
rv
al
,O
D
op
tic
al
de
ns
ity
Torzsa et al. BMC Infectious Diseases  (2017) 17:242 Page 4 of 8
Table 3 Estimated coefficients of the fitted logistic regression model for seropositivity,a before and after backward elimination
Characteristics Saturated model Final model
OR (95% CI) p-value OR (95% CI) p-value
Age 18–29 vs. 45–59 yearsb 1.64 (1.10–2.44) .015 1.67 (1.13–2.46) .0094
Age 30–44 vs. 45–59 yearsb 1.15 (0.78–1.70) .48 1.17 (0.80–1.71) .41
Age ≥60 vs. 45–59 yearsb 2.13 (1.46–3.12) <.0001 1.97 (1.39–2.80) .0002
Male vs. female 1.29 (1.00–1.67) .050 1.30 (1.01–1.68) .041
Vaccination yes vs. no 1.46 (0.92–2.29) .11 – –
Vaccination unknown vs. no 1.36 (0.90–2.05) .15 – –
Pertussis yes vs. no 0.99 (0.54–1.81) .97 – –
Pertussis unknown vs. no 0.99 (0.72–1.37) .96 – –
Medicationc yes vs. no 1.04 (0.71–1.54) .83 – –
Medicationc unknown vs. no 1.44 (0.62–3.33) .39 – –
Hospitalizationd yes vs. no 3.01 (0.79–11.55) .11 – –
Hospitalizationd unknown vs. no 1.03 (0.11–10.21) .98 – –
Current vs. never smoker 1.36 (0.99–1.87) .055 1.38 (1.01–1.89) .045
Former vs. never smoker 1.44 (1.07–1.95) .018 1.46 (1.08–1.97) .014
Abbreviations: CI confidence interval, OD optical density, OR odds ratio, vs. versus
a>0.3 OD units
bThe age group with the lowest seropositivity was used as the reference
cAny antibiotics and/or other medication (i.e., any cough medicines) for lower respiratory tract infections or (suspected) pertussis infections in the previous 12 months
dHospitalized due to respiratory infections in the previous 12 months
Table 4 Estimated coefficients of the fitted logistic regression model for increased likelihood of current/recent infection,a before and
after backward elimination
Characteristics Saturated model Final model
OR (95% CI) p-value OR (95% CI) p-value
Age 18–29 vs. 45–59 yearsb 0.57 (0.10–3.31) .53 0.58 (0.11–3.24) .54
Age 30–44 vs. 45–59 yearsb 1.21 (0.31–4.74) .79 1.21 (0.32–4.57) .78
Age ≥60 vs. 45–59 yearsb 3.60 (1.06–12.24) .040 2.99 (0.94–9.56) .064
Male vs. female 1.55 (0.65–3.70) .32 – –
Vaccination yes vs. no 2.03 (0.35–11.81) .43 – –
Vaccination unknown vs. no 3.31 (0.71–15.5) .13 – –
Pertussis yes vs. no 0.45 (0.06–3.64) .45 – –
Pertussis unknown vs. no 0.30 (0.08–1.08) .065 – –
Medicationc yes vs. no 1.24 (0.35–4.38) .74 – –
Medicationc unknown vs. no 2.14 (0.25–17.97) .49 – –
Hospitalizationd yes vs. no 0.00 (0.00–NR) .99 – –
Hospitalizationd unknown vs. no 0.00 (0.00–NR) 1.00 – –
Current vs. never smoker 7.08 (2.17–23.16) .0012 7.50 (2.32–24.31) .0008
Former vs. never smoker 4.12 (1.21–14.01) .024 4.07 (1.21–13.64) .023
Abbreviations: CI confidence interval, NR not reported, OD optical density, OR odds ratio, vs. versus
a≥1.0 OD units
bThe age group with the lowest seropositivity was used as the reference
cAny antibiotics and/or other medication (i.e., any cough medicines) for lower respiratory tract infections or (suspected) pertussis infections in the previous 12 months
dHospitalized due to respiratory infections in the previous 12 months
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pertussis infection. Although childhood vaccination rates in
Hungary are very high [6], immunity to pertussis wanes over
time [7–10], meaning that many adults are no longer pro-
tected. This could be overcome by the introduction of adult
pertussis boosters, an approach that has already been
adopted in various European countries [11] and the US [29].
In the current study, 1.1% of subjects had anti-PT
IgG levels ≥1.0 OD (indicative of current/recent
infection). It is difficult to compare this with other
studies, which have used a range of different assays,
cut-offs, and definitions, but infection within the last
year/recent/active infection rates of approximately 1–10%
have been reported in adults [22, 25, 27, 30–36],
which are similar to or higher than in the current
study.
In order to try to compare our seroprevalence results
with notified cases of pertussis, an estimation of pertus-
sis incidence based on seroprevalence data combined
with the manufacturer pre-defined cut-off values was
undertaken. Previously, de Melker et al. [37] used sero-
prevalence data combined with antibody decline over
time after infection to estimate incidence. Assuming that
“recent” relates to the previous year, 2/1999 subjects
(0.1%) with a level strongly indicative of current/recent
infection (≥1.5 OD units) in the current study would
translate into a crude annual incidence of pertussis in-
fection of 100/100,000. Similarly, the 22/1999 subjects
(1.1%) with a level indicative of current/recent infection
(≥1.0 OD units) would give a crude annual incidence of
1100/100,000. These crude incidences are roughly 500-
and 6000-fold higher than the notified rate among those
aged ≥20 years in Hungary in 2014 (approximately 0.19/
100,000) [13], indicating a very high level of underre-
porting. A recent review has found similar discrepancies
all around the world [16]. However, it should be noted
that the current study was not designed to perform this
type of calculation and “recent” (as defined by the
manufacturer) may not equate to 1 year. Therefore,
these estimations and comparisons should be interpreted
with caution.
The introduction of adult pertussis boosters could help
alleviate the burden of pertussis in this age group. It
may also help reduce the risk of transmission to suscep-
tible infants. Other approaches to protect infants prior
to their primary immunizations include cocooning or
immunization of pregnant women. Various European
countries [11] and the US [29] have introduced one or
other of these approaches to help protect newborns.
However, recent data indicate that post-partum vaccin-
ation of parents may not be as successful as maternal
vaccination during pregnancy [38–40]. Also, although
maternal immunization may benefit newborns, this ap-
proach alone would not address the burden of pertussis
in the adult population.
In the current study, seropositivity was significantly
more likely among those aged ≥60 and 18–29 years vs.
45–59 years; and there was a trend towards more likely
current/recent infection among those aged ≥60 years vs.
45–59 years. Overall, these results support waning im-
munity following childhood vaccinations, ultimately
resulting in higher levels of infection during later years.
The pertussis booster at age 11 years was introduced in
Hungary in 2006 [4], so some of the adults in the youn-
gest age group could have received this vaccination
approximately 7 or 8 years earlier. The remainder of the
population would probably have last received pertussis
vaccination ≥14 years ago; or never have been vacci-
nated. Although immunity wanes quite quickly after per-
tussis vaccination [41], anti-PT antibodies can persist for
up to approximately 10 years [42], therefore the elevated
rate of seropositivity in the 18–29-year age group is
likely due to adolescent (or even childhood) vaccination.
Among those aged ≥60 years, the elevated seropositivity
is likely related to pertussis infection, which was also ele-
vated in this age group. Based on these results, vaccin-
ation of the elderly could be beneficial in Hungary to
address the pertussis burden in this age group, who can
experience considerable pertussis-related morbidity [43].
Some other studies have also reported higher seroposi-
tivity among older adults [20, 23, 27]. However, others
have reported highest seropositivity rates in various
younger adult age groups [21, 24] or little variation by
age among adults [25]. Similarly, some previous studies
have reported a possible link between likely pertussis in-
fection and advancing age [20, 22, 31], but others have
reported no such link [25, 34, 35]. Whether these results
are indicative of true differences between countries and/
or years or whether they are due to a lack of sufficient
power to detect such differences is unclear.
Regarding gender, we found that males were signifi-
cantly more likely to be seropositive than females; but
not significantly more likely to have anti-PT IgG
levels indicative of current/recent infection. Higher
male seropositivity has also been reported in studies
from Mexico (p = .0007) [24] and Korea (p = .023)
[23]; but studies from Spain [26], Greece [21], and
The Gambia [22] have reported no significant differ-
ences in seropositivity between genders. Regarding
higher male likelihood of recent infection, this has
been reported to be significant in a study from The
Netherlands [31], non-significant in a study from
Denmark [34], higher but significance not reported in
one from The Gambia [22], or no significant gender
differences in two studies from China [35, 36]. Over-
all, it is unclear whether there is a true link between pertus-
sis and gender and, if there is, the cause is unknown.
Regarding smoking status, we found correlations be-
tween seropositivity and current/former smoking, and
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even stronger correlations between evidence of recent
pertussis infection and current/former smoking. This
could be because the epithelial cells of smokers have
been shown to have enhanced binding to Bordetella
pertussis [44], thus increasing pertussis infection risk.
However, a seroepidemiology study in Denmark found
no significant link between smoking status and recent
pertussis infection [34].
Limitations
Some of the subjects were enrolled into this study at a
regular GP visit, so the studied population may be sicker
and/or more health-conscious than the general population.
This method of recruitment probably also accounts for the
higher proportion of female subjects. Unfortunately, data
on the route of recruitment (GP visit, telephone call or
email) were not collected, so it is not possible to compare
results by route of recruitment. Also, although we recognize
that this “convenience sample” is a limitation of this study,
we feel that it is likely representative of the general
Hungarian adult population.
As there is no agreed threshold of anti-PT antibodies
that provide protection, seroprevalence studies are no-
toriously difficult to interpret. Also, the manufacturer’s
definition of “current/recent” infection is rather vague,
making comparisons with other studies difficult. Lastly,
p-values were not adjusted for multiplicity of endpoints
(as there was only one endpoint of interest), so the stat-
istical significance of the results should be interpreted
with caution.
Conclusions
In this seroprevalence study, 14.8% of adults in Hungary
were found to be seropositive for anti-PT IgG antibodies,
with increased risk among males, those aged ≥60 or 18–
29 years, and current/former smokers. The remaining
85.2% of adults were seronegative, and therefore at risk of
pertussis infection. Furthermore, 1.1% of adults had evi-
dence of current/recent pertussis infection, with increased
risk among current/former smokers and a trend towards
an increased risk among those aged ≥60 years. This gives
an estimated crude annual pertussis incidence of 1100/
100,000, roughly 6000-fold higher than the notified rate in
Hungary. This indicates that many adults in Hungary may
have undiagnosed pertussis, and this could be unknow-
ingly transmitted to susceptible infants. The introduction
of additional pertussis boosters during adulthood could
help overcome this potential issue.
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